{"id":"nbp607-tiv","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a therapeutic vaccine candidate, NBP607-TIV aims to stimulate both cellular and humoral immune responses against influenza antigens. The vaccine is being developed to provide broader protection and potentially therapeutic benefit in influenza-infected patients, moving beyond traditional prophylactic vaccination approaches.","oneSentence":"NBP607-TIV is a therapeutic influenza vaccine designed to enhance immune response against multiple influenza virus strains.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:50:19.929Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza treatment and prevention"}]},"trialDetails":[{"nctId":"NCT03704740","phase":"PHASE3","title":"Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2018-10-25","conditions":"Influenza","enrollment":676},{"nctId":"NCT02467842","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-10","conditions":"Influenza","enrollment":1503},{"nctId":"NCT03893669","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2012-09","conditions":"Prevention of Influenza","enrollment":100},{"nctId":"NCT03020628","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2016-10","conditions":"Influenza, Human","enrollment":171},{"nctId":"NCT02621177","phase":"PHASE3","title":"Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2013-11","conditions":"Influenza, Human","enrollment":385},{"nctId":"NCT02621164","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-09","conditions":"Influenza, Human","enrollment":454},{"nctId":"NCT02344134","phase":"PHASE3","title":"Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2013-09","conditions":"Influenza, Human","enrollment":1155}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NBP607-TIV","genericName":"NBP607-TIV","companyName":"SK Chemicals Co., Ltd.","companyId":"sk-chemicals-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"NBP607-TIV is a vaccine used for the prevention of influenza. It is a quadrivalent vaccine, as indicated by its inclusion in ClinicalTrials.gov under the intervention \"NBP607-QIV\".","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}